I call this meeting to order.
Welcome to meeting number 136 of the House of Commons Standing Committee on Health.
In accordance with our routine motion, I am informing the committee that all remote participants have completed the required connection tests in advance of the meeting.
Pursuant to an order of reference of May 29, 2024, the committee will resume its study of Bill C-368, an act to amend the Food and Drugs Act with regard to natural health products.
I would like to welcome our panel of witnesses.
Representing the Canadian Federation of Independent Business, we have Jasmin Guénette, vice-president of national affairs; and Michelle Auger, senior policy analyst, national affairs.
Representing the Canadian Health Food Association, we have Aaron Skelton, president and CEO, appearing virtually; and Jules Gorham, director of regulatory affairs and policy.
On behalf of the Direct Sellers Association of Canada, we have Peter Maddox, president.
Finally, on behalf of Food, Health & Consumer Products of Canada, we have Gerry Harrington, senior vice-president, consumer health; and Roberta Kramchynsky, vice-president, health policy and regulatory affairs.
Thank you all for being with us today. We'll begin with opening statements of five minutes per organization, starting with the Canadian Federation of Independent Business.
I understand that Jasmin Guénette will be speaking for the CFIB.
Welcome to the committee. You have the floor.